title: [Multiple sclerosis vaccine: possibilities of the use of dendritic cells immunomodulatory potential].
abstract: For the first time we carried out a clinical assessment of the safety, tolerability and clinical efficacy course of repeated administration of experimental modified autologous vaccine interleykin (IL-10) dendritic cells in two patients with secondary-progressive multiple sclerosis patient and one with relapsing-remitting multiple sclerosis. In the course of treatment, we carried out clinical and immunological monitoring. It was found out that intradermal dose of 3 x 10⁶ cells applied to spinal area 6-12. times did not cause any serious side effects. After the treatment with dendritic cells, the following results were observed: 1) a significant positive clinical effect in patients with secondary-progressive multiple sclerosis exacerbations; 2) moderate positive clinical effect in patients with relapsing-remitting multiple sclerosis, in a state of remission; 3) a complete absence of any clinical results in patients with secondary-progressive multiple sclerosis without exacerbations. The immune response was characterized by a significant absolute and relative increase of serum T-regulatory cells. Discovered distinct anti-inflammatory properties of dendritic cell therapy allow us to consider it as a promising area of personalized treatment based on an individual vaccination against multiple sclerosis.
authors.forename: M M
authors.initials: MM
authors.lastname: Odinak
authors.forename: G N
authors.initials: GN
authors.lastname: Bisaga
authors.forename: V S
authors.initials: VS
authors.lastname: Chirskii
authors.forename: M V
authors.initials: MV
authors.lastname: Pashchenkov
authors.forename: I A
authors.initials: IA
authors.lastname: Baldueva
authors.forename: V M
authors.initials: VM
authors.lastname: Moiseenko
authors.forename: T L
authors.initials: TL
authors.lastname: Nekhaeva
authors.forename: N M
authors.initials: NM
authors.lastname: Kalinina
authors.forename: N I
authors.initials: NI
authors.lastname: Davydova
authors.forename: N V
authors.initials: NV
authors.lastname: Bychkova
authors.forename: A V
authors.initials: AV
authors.lastname: Pozdnyakov
mesh_terms: D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016753:Interleukin-10 / Q000276:immunology*; D015847:Interleukin-4 / Q000276:immunology; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000097:blood / Q000276:immunology / Q000628:therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000276:immunology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology; D016896:Treatment Outcome; D014612:Vaccines / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D014612:Vaccines; D016753:Interleukin-10; D015847:Interleukin-4